Stockscreener 앱 받기
19.79
1.49%
-0.30
시간 외 거래:
19.79
전일 마감가:
$20.09
열려 있는:
$20.11
하루 거래량:
694.59K
Relative Volume:
0.82
시가총액:
$1.35B
수익:
$330.50M
순이익/손실:
$145.42M
주가수익비율:
11.99
EPS:
1.65
순현금흐름:
$157.96M
1주 성능:
-4.30%
1개월 성능:
+1.12%
6개월 성능:
+14.06%
1년 성능:
+19.94%
1일 변동 폭
$19.76
$20.18
1주일 범위
$19.68
$20.84
52주 변동 폭
$16.18
$22.00
Innoviva Inc Stock (INVA) Company Profile
명칭
Innoviva Inc
전화
(650) 238-9600
주소
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
INVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
19.79 | 1.35B | 330.50M | 145.42M | 157.96M | 1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-20 | 개시 | Goldman | Neutral |
| 2017-11-20 | 개시 | Deutsche Bank | Hold |
Innoviva Inc 주식(INVA)의 최신 뉴스
Rhumbline Advisers Sells 9,188 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
FDA Grants Priority Review for Innoviva's (INVA) Zoliflodacin | - GuruFocus
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 - Kalkine Media
FDA reviews new gonorrhea antibiotic from Innoviva By Investing.com - Investing.com South Africa
FDA Reviews Innoviva's (INVA) Zoliflodacin for Gonorrhea Treatment - GuruFocus
Innoviva Says FDA Accepts New Drug Application for Zoliflodacin - MarketScreener
Innoviva Specialty's gonorrhea antibiotic to undergo FDA review (INVA) - Seeking Alpha
FDA reviews new gonorrhea antibiotic from Innoviva - Investing.com Australia
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults - BioSpace
Innoviva (INVA) Awaits FDA Decision on New Gonorrhea Antibiotic | INVA Stock News - GuruFocus
Transcript : Innoviva, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01 - MarketScreener
Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma (NASDAQ:INVA) - Seeking Alpha
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Innoviva, Inc. (NASDAQ:INVA) - Defense World
INVA stock touches 52-week high at $21.35 amid robust gains - Investing.com Nigeria
Innoviva to Participate in Upcoming Investor Conferences - BioSpace
(INVA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $546,000 Holdings in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Ameriprise Financial Inc. Has $2.50 Million Holdings in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Innoviva, Inc. (NASDAQ:INVA) Stock Holdings Lifted by Millennium Management LLC - Defense World
(INVA) Proactive Strategies - news.stocktradersdaily.com
Innoviva Elects Board Members and Approves Compensation - TipRanks
Bank of America Corp DE Decreases Holdings in Innoviva, Inc. (NASDAQ:INVA) - Defense World
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections - BioSpace
Innoviva (INVA) Launches New Antibiotic ZEVTERA for MRSA Treatme - GuruFocus
ZEVTERA(Ceftobiprole), An Advanced-Generation Cephalosporin Antibiotic Now Commercially Available In The U.S. To Treat Three Types Of Bacterial Infections - marketscreener.com
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States - The Manila Times
Cubist Systematic Strategies LLC Makes New $184,000 Investment in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Innoviva, Inc. (NASDAQ:INVA) Shares Bought by Northern Trust Corp - Defense World
Comerica Bank Sells 141,150 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Armata Completes Crucial Bacteriophage Trial, Lands $4.65M Defense Contract Amid Strong Q1 Results - Stock Titan
(INVA) Investment Analysis - news.stocktradersdaily.com
Investor Network: Innoviva, Inc. to Host Earnings Call - ACCESS Newswire
Envestnet Asset Management Inc. Has $258,000 Stock Position in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling - Insider Monkey
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress - BioSpace
Innoviva: Q1 Earnings Snapshot - MySA
Innoviva Inc reports results for the quarter ended March 31Earnings Summary - TradingView
INVA Posts Strong Q1 Results with Revenue Growth and Strategic Developments | INVA Stock News - GuruFocus
BlackRock, Inc. Reduces Stake in Innoviva Inc: A Detailed Analysis - GuruFocus
Wells Fargo & Company MN Purchases 10,637 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Trading (INVA) With Integrated Risk Controls - news.stocktradersdaily.com
Innoviva (NASDAQ:INVA) Stock Rating Upgraded by StockNews.com - Defense World
Rep. George Whitesides Unloads Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Rep. George Whitesides Sells Off Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Innoviva Inc (INVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Innoviva Inc 주식 (INVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | 10% Owner |
Mar 05 '25 |
Sale |
17.63 |
270,374 |
4,766,126 |
6,855,451 |
| DENNER ALEXANDER J | 10% Owner |
Mar 04 '25 |
Sale |
17.63 |
151,175 |
2,665,079 |
7,125,825 |
0.39%
0.42%
자본화:
|
볼륨(24시간):